These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31898163)

  • 21. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study.
    Naumann M; Lowe NJ; Kumar CR; Hamm H;
    Arch Dermatol; 2003 Jun; 139(6):731-6. PubMed ID: 12810503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and prolonged efficacy of Botulin Toxin A in primary hyperhidrosis.
    D'Epiro S; Macaluso L; Salvi M; Luci C; Mattozzi C; Marzocca F; Salvo V; Scarnò M; Calvieri S; Richetta AG
    Clin Ter; 2014; 165(6):e395-400. PubMed ID: 25524193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Duration of efficacy increases with the repetition of botulinum toxin A injections in primary axillary hyperhidrosis: a study in 83 patients.
    Lecouflet M; Leux C; Fenot M; Célerier P; Maillard H
    J Am Acad Dermatol; 2013 Dec; 69(6):960-4. PubMed ID: 24035554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study.
    Vadoud-Seyedi J; Simonart T
    Br J Dermatol; 2007 May; 156(5):986-9. PubMed ID: 17286630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum toxin B in the treatment of craniofacial hyperhidrosis.
    Karlqvist M; Rosell K; Rystedt A; Hymnelius K; Swartling C
    J Eur Acad Dermatol Venereol; 2014 Oct; 28(10):1313-7. PubMed ID: 24118460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis.
    Baumann L; Slezinger A; Halem M; Vujevich J; Martin LK; Black L; Bryde J
    Int J Dermatol; 2005 May; 44(5):418-24. PubMed ID: 15869543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reconstituted and frozen botulinum toxin A is as effective and safe as fresh for treating axillary hyperhidrosis: A retrospective study.
    Shayesteh A; Boman A; Hawas E; Carlberg B
    PLoS One; 2023; 18(12):e0295393. PubMed ID: 38048338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term quantitative benefits of botulinum toxin type A in the treatment of axillary hyperhidrosis.
    Odderson IR
    Dermatol Surg; 2002 Jun; 28(6):480-3. PubMed ID: 12081675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose botulinum toxin type A therapy for axillary hyperhidrosis markedly prolongs the relapse-free interval.
    Wollina U; Karamfilov T; Konrad H
    J Am Acad Dermatol; 2002 Apr; 46(4):536-40. PubMed ID: 11907503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors associated with efficacy of botulinum toxin a injections in primary axillary hyperhidrosis: A retrospective study of ninety patients.
    Bérard M; Leducq S; Laribi K; Samaran R; Maillard H
    Dermatol Ther; 2022 Aug; 35(8):e15620. PubMed ID: 35669995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of focal hyperhidrosis with botulinum toxin type A: long-term follow-up in 61 patients.
    Schnider P; Moraru E; Kittler H; Binder M; Kranz G; Voller B; Auff E
    Br J Dermatol; 2001 Aug; 145(2):289-93. PubMed ID: 11531794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The place of botulinum toxin type A in the treatment of focal hyperhidrosis.
    Lowe N; Campanati A; Bodokh I; Cliff S; Jaen P; Kreyden O; Naumann M; Offidani A; Vadoud J; Hamm H
    Br J Dermatol; 2004 Dec; 151(6):1115-22. PubMed ID: 15606505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Injectable botulinum toxin as a treatment for plantar hyperhidrosis: a case study.
    Vlahovic TC; Dunn SP; Blau JC; Gauthier C
    J Am Podiatr Med Assoc; 2008; 98(2):156-9. PubMed ID: 18347128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Botulinum Toxin Versus Placebo: A Meta-Analysis of Treatment and Quality-of-life Outcomes for Hyperhidrosis.
    Obed D; Salim M; Bingoel AS; Hofmann TR; Vogt PM; Krezdorn N
    Aesthetic Plast Surg; 2021 Aug; 45(4):1783-1791. PubMed ID: 33619611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of focal hyperhidrosis.
    Murray CA; Cohen JL; Solish N
    J Cutan Med Surg; 2007; 11(2):67-77. PubMed ID: 17374317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of a 10-year follow-up study of botulinum toxin A therapy for primary axillary hyperhidrosis in Australia.
    Rosen R; Stewart T
    Intern Med J; 2018 Mar; 48(3):343-347. PubMed ID: 29512329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between Dermatology Life Quality Index and Minor test and differences in their levels over time in patients with axillary hyperhidrosis treated with botulinum toxin type A.
    Skroza N; Bernardini N; La Torre G; La Viola G; Potenza C
    Acta Dermatovenerol Croat; 2011; 19(1):16-20. PubMed ID: 21489361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of focal idiopathic hyperhidrosis with Botulinum Toxin Type A: clinical predictive factors of relapse-free survival.
    Campanati A; Sandroni L; Gesuita R; Giuliano A; Giuliodori K; Marconi B; Ganzetti G; Offidani A
    J Eur Acad Dermatol Venereol; 2011 Aug; 25(8):917-21. PubMed ID: 21054569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Liposuction curettage versus Botox for axillary hyperhidrosis. A prospective study of the quality of life].
    Ottomann C; Blazek J; Hartmann B; Muehlberger T
    Chirurg; 2007 Apr; 78(4):356-61. PubMed ID: 17226006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Botulinum toxin A injections in the treatment of axillary hyperhidrosis: a prospective study reviewing quality of life and patient satisfaction in a UK tertiary dermatology centre.
    Asfour L; Moussa A; Littlewood Z; Sharif J; Newsham J; O'Donoghue N; Ogden S; McMullen E; Hunter H
    Clin Exp Dermatol; 2022 Jul; 47(7):1358-1359. PubMed ID: 35262223
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.